Pyridoxal 5'-phosphate binds specifically to soluble CD4 protein, the HIV- 1 receptor. Implications for AIDS therapy

J. M. Salhany, L. M. Schopfer

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Considerable effort is being made to design anti-viral drugs for the human immunodeficiency virus type 1 (HIV-1) infection process. Some of this work has focused on CD4 protein, the HIV-1 receptor on T helper lymphocytes. One drug that binds to CD4 protein and inhibits both viral infection and growth is DIDS (4,4'-diisothiocyanato-2,2'-stilbenedisulfonate). DIDS is best known for its ability to inhibit erythrocyte band 3 anion exchange. Although the antiviral potency of DIDS is evident in vitro (IC50 ~ 30 μM), intravenous administration of DIDS should not be effective owing to the large number of band 3 molecules present on the red blood cell membrane (~106/cell), and to the very small K(d) for DIDS binding to band 3 (~30 nM). Therefore, we sought to identify other anion transport inhibitors that would bind weakly to band 3, but tightly to CD4 protein, and that could be administered to humans without significant toxic side effects. On the basis of our previous work with band 3 (Salhany, J. M., Rauenbuehler, P. B., and Sloan, R. L. (1987) J. Biol. Chem. 262, 15965-15973), we elected to study the binding of pyridoxal 5'-phosphate (PLP) to soluble CD4 protein. We have discovered that PLP binds surprisingly tightly to soluble CD4 protein (K(d) = 45 μM), with a stoichiometry of about 1 mol of PLP/mol of protein. Furthermore, PLP binding was found to be competitive with DIDS for its binding site on soluble CD4 protein. These results suggest that PLP may be an effective anti-viral agent for the HIV-1 infection process.

Original languageEnglish (US)
Pages (from-to)7643-7645
Number of pages3
JournalJournal of Biological Chemistry
Volume268
Issue number11
StatePublished - Jan 1 1993

Fingerprint

HIV Receptors
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid
Human Immunodeficiency Virus Proteins
Pyridoxal Phosphate
HIV-1
Acquired Immunodeficiency Syndrome
Virus Diseases
Proteins
Viruses
Anions
Antiviral agents
Therapeutics
Erythrocytes
Virus Receptors
Lymphocytes
Poisons
Cell membranes
Helper-Inducer T-Lymphocytes
Stoichiometry
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Pyridoxal 5'-phosphate binds specifically to soluble CD4 protein, the HIV- 1 receptor. Implications for AIDS therapy. / Salhany, J. M.; Schopfer, L. M.

In: Journal of Biological Chemistry, Vol. 268, No. 11, 01.01.1993, p. 7643-7645.

Research output: Contribution to journalArticle

@article{c27847908c004a108f5083faa34060bc,
title = "Pyridoxal 5'-phosphate binds specifically to soluble CD4 protein, the HIV- 1 receptor. Implications for AIDS therapy",
abstract = "Considerable effort is being made to design anti-viral drugs for the human immunodeficiency virus type 1 (HIV-1) infection process. Some of this work has focused on CD4 protein, the HIV-1 receptor on T helper lymphocytes. One drug that binds to CD4 protein and inhibits both viral infection and growth is DIDS (4,4'-diisothiocyanato-2,2'-stilbenedisulfonate). DIDS is best known for its ability to inhibit erythrocyte band 3 anion exchange. Although the antiviral potency of DIDS is evident in vitro (IC50 ~ 30 μM), intravenous administration of DIDS should not be effective owing to the large number of band 3 molecules present on the red blood cell membrane (~106/cell), and to the very small K(d) for DIDS binding to band 3 (~30 nM). Therefore, we sought to identify other anion transport inhibitors that would bind weakly to band 3, but tightly to CD4 protein, and that could be administered to humans without significant toxic side effects. On the basis of our previous work with band 3 (Salhany, J. M., Rauenbuehler, P. B., and Sloan, R. L. (1987) J. Biol. Chem. 262, 15965-15973), we elected to study the binding of pyridoxal 5'-phosphate (PLP) to soluble CD4 protein. We have discovered that PLP binds surprisingly tightly to soluble CD4 protein (K(d) = 45 μM), with a stoichiometry of about 1 mol of PLP/mol of protein. Furthermore, PLP binding was found to be competitive with DIDS for its binding site on soluble CD4 protein. These results suggest that PLP may be an effective anti-viral agent for the HIV-1 infection process.",
author = "Salhany, {J. M.} and Schopfer, {L. M.}",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
volume = "268",
pages = "7643--7645",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "11",

}

TY - JOUR

T1 - Pyridoxal 5'-phosphate binds specifically to soluble CD4 protein, the HIV- 1 receptor. Implications for AIDS therapy

AU - Salhany, J. M.

AU - Schopfer, L. M.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Considerable effort is being made to design anti-viral drugs for the human immunodeficiency virus type 1 (HIV-1) infection process. Some of this work has focused on CD4 protein, the HIV-1 receptor on T helper lymphocytes. One drug that binds to CD4 protein and inhibits both viral infection and growth is DIDS (4,4'-diisothiocyanato-2,2'-stilbenedisulfonate). DIDS is best known for its ability to inhibit erythrocyte band 3 anion exchange. Although the antiviral potency of DIDS is evident in vitro (IC50 ~ 30 μM), intravenous administration of DIDS should not be effective owing to the large number of band 3 molecules present on the red blood cell membrane (~106/cell), and to the very small K(d) for DIDS binding to band 3 (~30 nM). Therefore, we sought to identify other anion transport inhibitors that would bind weakly to band 3, but tightly to CD4 protein, and that could be administered to humans without significant toxic side effects. On the basis of our previous work with band 3 (Salhany, J. M., Rauenbuehler, P. B., and Sloan, R. L. (1987) J. Biol. Chem. 262, 15965-15973), we elected to study the binding of pyridoxal 5'-phosphate (PLP) to soluble CD4 protein. We have discovered that PLP binds surprisingly tightly to soluble CD4 protein (K(d) = 45 μM), with a stoichiometry of about 1 mol of PLP/mol of protein. Furthermore, PLP binding was found to be competitive with DIDS for its binding site on soluble CD4 protein. These results suggest that PLP may be an effective anti-viral agent for the HIV-1 infection process.

AB - Considerable effort is being made to design anti-viral drugs for the human immunodeficiency virus type 1 (HIV-1) infection process. Some of this work has focused on CD4 protein, the HIV-1 receptor on T helper lymphocytes. One drug that binds to CD4 protein and inhibits both viral infection and growth is DIDS (4,4'-diisothiocyanato-2,2'-stilbenedisulfonate). DIDS is best known for its ability to inhibit erythrocyte band 3 anion exchange. Although the antiviral potency of DIDS is evident in vitro (IC50 ~ 30 μM), intravenous administration of DIDS should not be effective owing to the large number of band 3 molecules present on the red blood cell membrane (~106/cell), and to the very small K(d) for DIDS binding to band 3 (~30 nM). Therefore, we sought to identify other anion transport inhibitors that would bind weakly to band 3, but tightly to CD4 protein, and that could be administered to humans without significant toxic side effects. On the basis of our previous work with band 3 (Salhany, J. M., Rauenbuehler, P. B., and Sloan, R. L. (1987) J. Biol. Chem. 262, 15965-15973), we elected to study the binding of pyridoxal 5'-phosphate (PLP) to soluble CD4 protein. We have discovered that PLP binds surprisingly tightly to soluble CD4 protein (K(d) = 45 μM), with a stoichiometry of about 1 mol of PLP/mol of protein. Furthermore, PLP binding was found to be competitive with DIDS for its binding site on soluble CD4 protein. These results suggest that PLP may be an effective anti-viral agent for the HIV-1 infection process.

UR - http://www.scopus.com/inward/record.url?scp=0027457999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027457999&partnerID=8YFLogxK

M3 - Article

C2 - 8463294

AN - SCOPUS:0027457999

VL - 268

SP - 7643

EP - 7645

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 11

ER -